Literature DB >> 19524312

Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.

Andrew Chan, Daren Teoh, Paul Sanghera, Andrew Hartley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19524312     DOI： 10.1016/j.radonc.2009.05.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


× No keyword cloud information.
  2 in total

1.  Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma.

Authors:  Francesca De Felice; Luigia Vetrone; Nadia Bulzonetti; Rossella Caiazzo; Francesco Marampon; Daniela Musio; Vincenzo Tombolini
Journal:  Med Oncol       Date:  2019-06-12       Impact factor: 3.064

2.  Cetuximab: its unique place in head and neck cancer treatment.

Authors:  Pol Specenier; Jan B Vermorken
Journal:  Biologics       Date:  2013-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.